|Bid||2.2000 x 1000|
|Ask||4.5000 x 1000|
|Day's Range||2.0500 - 2.8400|
|52 Week Range||1.3500 - 6.4000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 20, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.80|
The Company will host a conference call at 8:30 am Eastern Time to discuss the results and provide a corporate update. A live audio webcast of the presentation will be available via the “Investor Relations” page of the Entera Bio website, www.enterabio.com, or by clicking here. A replay of the webcast will be archived on Entera website for approximately 45 days following the call. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The Company is initially applying its technology to develop an oral formulation of a human parathyroid hormone analog, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis.
JERUSALEM, Israel, Aug. 05, 2019 -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip.
Entera Bio Ltd. (ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH (1-34) tablet. This double blinded, placebo controlled, dose-ranging study will evaluate three different doses in postmenopausal women with low bone mass. Human PTH (1-34) is a known anabolic treatment currently available as a daily subcutaneous injection, Forteo® (marketed by Eli Lilly®) with a known effect on bone formation biomarkers and bone mineral density (BMD).
Entera Bio recently entered into a $270 million license agreement with Amgen. Entera Bio's platform technology enables oral therapies based on molecules that would otherwise undergo gastric degradation and have limited or no bioavailability.
Phase 2b Study for oral PTH in osteoporosis to begin by mid-year 2019Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Data processing and statistical.
Entera Bio Ltd. (ENTX) announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018, with the U.S. Securities and Exchange Commission. Upon request, Entera Bio will send a copy of the Annual Report to any requesting shareholder. Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs.
Positive feedback and guidance from the US FDA regarding development plans for Oral PTH in osteoporosisEntered into research collaboration and license agreement with Amgen,.
JERUSALEM, March 27, 2019 -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the fourth quarter and year ended December 31, 2018.
Entera Bio Ltd. (ENTX), announced today that Mira Rosenzweig, Chief Financial Officer, will be leaving the Company in mid-April 2019 on amicable terms to pursue other professional opportunities closer to her home. Ms. Rosenzweig has confirmed to us that she has no disagreement with the presentation of the Company’s financial statements or accounting policies. “The company appreciates Mira’s dedication and significant contributions to the progress at Entera over the past several years, including the completion of an IPO on the Nasdaq in July 2018.
Entera Bio Ltd. (ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food and Drug Administration (FDA) to discuss the Company’s development plan for Oral PTH for the treatment of osteoporosis. The feedback and guidance were summarized in the formal meeting minutes that Entera subsequently received from the FDA. In addition to discussing various aspects of the nonclinical and clinical development plan, the meeting focused on the 505 b(2) regulatory pathway and the use of bone mineral density (BMD) rather than fracture incidence as the primary endpoint to support a New Drug Application (NDA). Based on the FDA's response, Entera believes that the Phase 3 study may use BMD as the primary efficacy endpoint and that a fracture endpoint study will not be required.
Entered into research collaboration and license agreement with Amgen, potential for up to $270 million in milestone payments, as well as royalties on commercial salesMet with.
JERUSALEM, Jan. 10, 2019 -- Entera Bio Ltd. (Nasdaq: ENTX) announced today the appointment of Gerald M. Ostrov as a new independent director on its Board of Directors,.
Entera Bio Ltd. (ENTX) announced today that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses. Entera will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected.
Entera Bio Ltd. (ENTX) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug [“Oral PTH (1-34)”]. “The results from Part 1 of the PK/PD study in patients with hypoparathyroidism have confirmed that Oral PTH (1-34) activates biological pathways that PTH is known to regulate.